Cardiovascular Safety of Phosphodiesterase Type 5 Inhibitors After Nearly 2 Decades on the Market.
Authors:Robert A Kloner|||Irwin Goldstein|||Michael G Kirby|||John D Parker|||Richard Sadovsky
Journal: Sexual medicine reviews
Publication Type: Journal Article
Date: 2018
DOI: 10.1016/j.sxmr.2018.03.008
ID: 29960874
Affiliations:
Affiliations
Huntington Medical Research Institutes, Pasadena, CA, USA; Division of Cardiovascular Medicine, Department of Medicine, Keck School of Medicine at University of Southern California, Los Angeles, CA, USA. Electronic address: robert.kloner@hmri.org.|||Sexual Medicine, Alvarado Hospital, San Diego, CA, USA.|||Prostate Center, London, United Kingdom; University of Hertfordshire, Center for Research in Primary and Community Care, Hatfield, United Kingdom.|||Division of Cardiology, Department of Medicine, University of Toronto and Mount Sinai Hospital and Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada.|||Department of Family Medicine, State University of New York Downstate Medical Center, Brooklyn, NY, USA.
Abstract
The phosphodiesterase-5 (PDE5) inhibitors that have been available for nearly 20 years are highly effective in treating erectile dysfunction and have been consistently shown to be safe when used according to package insert instructions.
